ERBB2 and neoplasm: Pathology reports should include the semiquantitative IHC score, and whenever feasible the most recent tumor specimen (archival or new biopsy) should be tested to account for heterogeneity and phenotype evolution; many pivotal protocols mandated central confirmation of HER2-low status prior to randomization [47].